c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

about

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

Item

http://www.wikidata.org/entity/Q47124745

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

@en

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

@nl

type

Item

label

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

@en

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

@nl

prefLabel

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

@en

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

@nl

P1476

c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

@en

P2093

Han Seok Ko

http://www.w3.org/2001/XMLSchema#string

Preston Ge

http://www.w3.org/2001/XMLSchema#string

Saebom Lee

http://www.w3.org/2001/XMLSchema#string

Saurav Brahmachari

http://www.w3.org/2001/XMLSchema#string

Senthilkumar S Karuppagounder

http://www.w3.org/2001/XMLSchema#string

Valina L Dawson

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's Disease: Genetics and Pathogenesis

PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease

PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function

ABL tyrosine kinases: evolution of function, regulation, and specificity

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease

Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease

Dopamine covalently modifies and functionally inactivates parkin

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

P304

589-601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JPD-171191

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ted M. Dawson

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29103051

http://www.w3.org/2001/XMLSchema#string

P932

5676866

http://www.w3.org/2001/XMLSchema#string